NCT02670161 - Quality Improvement and Practice Based Research in Neurology Using the EMR | Biotech Hunter

Enrollment

3,300

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Brain TumorsEpilepsyMigraineMild Cognitive ImpairmentConcussionMultiple SclerosisNeuropathyParkinson'sRestless Legs SyndromeStroke

Interventions

DRUG

Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)

brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).

Trial Locations (1)

60201

NorthShore University HealthSystem, Evanston